Indole based prostate cancer agents-Reference-Cited by-同舟云学术

Indole based prostate cancer agents

Published:2022-01-13 Issue:0 Volume:0 Page:
ISSN:2365-6581
Container-title:Physical Sciences Reviews
language:en
Short-container-title:

Author:

Kumar Sunil¹²,Patil Madhuri T.³,Salunke Deepak B.¹⁴

Affiliation:

1. Department of Chemistry and Centre for Advanced Studies in Chemistry , Panjab University , Chandigarh , 160014 , India

2. Department of Chemistry , J. C. Bose University of Science and Technology, YMCA , Faridabad 121006 , Haryana , India

3. Mehr Chand Mahajan DAV College for Women , Sector 36A , Chandigarh 160036 , India

4. National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials , Panjab University , Chandigarh 160014 , India

Abstract

Abstract Cancer weakens the immune system which fails to fight against the rapidly growing cells. Among the various types of cancers, prostate cancer (PCa) is causing greater number of deaths in men after lung cancer, demanding advancement to prevent, detect and treat PCa. Several small molecule heterocycles and few peptides are being used as oncological drugs targeting PCa. Heterocycles are playing crucial role in the development of novel cancer chemotherapeutics as well as immunotherapeutics. Indole skeleton, being a privileged structure has been extensively used for the discovery of novel anticancer agents and the application of indole derivatives against breast cancer is well documented. The present article highlights the usefulness of indole linked heterocyclic compounds as well as the fused indole derivatives against prostate cancer.

Publisher

Walter de Gruyter GmbH

Subject

General Physics and Astronomy,General Materials Science,General Chemistry

Link

https://www.degruyter.com/document/doi/10.1515/psr-2021-0131/pdf

Reference56 articles.

1. U.S. Cancer Statistics Working Group. U.S. Cancer statistics data visualizations tool, based on November 2017 submission data (1999–2015). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2018. Available from: www.cdc.gov/cancer/dataviz.

2. Pietro, GD, Chornokur, G, Kumar, NB, Davis, C, Park, JY. Racial differences in the diagnosis and treatment of prostate cancer. Int Neurourol J 2016;20:S112–9. https://doi.org/10.5213/inj.1632722.361.

3. Li, J, Mercer, E, Gou, X, Lu, Y-J. Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. Am J Cancer Res 2013;3:127–51.

4. Howlader, N, Noone, AM, Krapcho, M, Miller, D, Brest, A, Yu, M, et al., editors. SEER cancer statistics review, 1975–2016. Bethesda, MD: National Cancer Institute; 2019. Available from: https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

5. (i)Sobel, RE, Sadar, MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. J Urol 2005;173:360–72. https://doi.org/10.1097/01.ju.0000149989.01263.dc.